- AbbVie (NYSE:ABBV) has completed its acquisition of clinical-stage biotech Capstan Therapeutics.
- The deal, first announced in late June, is worth up to $2.1B.
- Captan’s lead asset, CPTX2309, is a targeted lipid nanoparticle, anti-CD19 CAR-T therapy for B cell-mediated autoimmune diseases in phase 1.
AbbVie closes Capstan Therapeutics acquisition
